One in two people will be diagnosed with cancer during his/her lifetime
Imagine if it was possible with a blood-based biomarker test to help and enable doctors:
-
to detect multiple cancers susceptibility
-
to detect cancer progression or relapse
How could it impact a patient’s journey with cancer?
We are here to help you discover that possibility with two new tools for physicians:
Cancer facts
One in two people will be diagnosed with cancer during his/her lifetime
Cancer susceptibility detection is the key
Today screening tests:
-
can not detect several types of cancer
-
do not allow efficient detection of tumors at early stages
Reliable detection of cancer at an early stage before symptoms appear has the potential to dramatically decrease global cancer mortality.
Innovative answer
1.
ECS progastrin's approach
An efficient screening test should meet the following criteria :
RELIABLE
REPRODUCTIBLE
AFFORDABLE
VALID FOR MULTIPLE CANCERS
SIMPLE
2.
A new tool to help physicians to detect multiple cancers susceptibility at early stages
ECS-progastrin has developed the first true test for helping early cancer screening working for multiple cancers and meeting all these criteria. Called DxPG80, this IVD test is able to detect a specific biomarker in the blood: hPG80 (Progastrin).
In almost all types of cancers, at the earliest stages of development, there is an uncontrolled activation of the Wnt oncogenic pathway. This uncontrolled activation of the Wnt oncogenic pathway is vital for the cancer cells to grow and survive. It induces the expression of multiple genes required for the cancer cells to grow and survive. Among these multiple genes, there is the gene coding for our target: Progastrin.
DxPG80 IVD test is CE marqued under the project name cancerREAD. Regulatory revisions are ongoing.
3.
Efficient technology
Under pathological condition:
However, in tumors, progastrin produced by cancer cells is not maturated in gastrin, leading to the secretion of progastrin and thus to its presence in the blood. Therefore we can specifically detect Progastrin in the blood of persons having a cancer.
Under physiological condition:
Progastrin is a pro-hormone that is processed in gastrin, an hormone that is secreted during digestion by specific cells of the stomach, that stimulates the normal secretion of gastric acid. In these physiological conditions, and outside the digestion time, progastrin is not present in the blood.
DxPG80 IVD test is based on the ELISA technique that is the most reliable and the most routinely used assay to detect biomarkers on the blood.
ELISA is a test that combines the specificity of antibodies with the sensitivity of enzyme assays, by using antibodies coupled to an easily-assayed enzyme. A color change shows the presence of the biomarker.
Scientific Committee
Éric Thieulin
President
Dominique Joubert-Floch, Ph.D. in biology
Senior Scientific Consultant
Alexandre Prieur,
Ph.D. in oncology
Chief Scientific Officer
François Dupoteau
Chief Technology Officer
To share its medical & scientific results with you, ECS progastrin is proud to be present at major cancer congresses
Secure your future
It's time to control cancer
Contact us
ECS progastrin
Chemin de la Meunière 12
Prilly 1008 Suisse